Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in WT, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! Please amend your records accordingly. The old numbers will work until the end of 2017 only!

SynAging will be present at the following meetings in 2017:

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings in 2016:

Press & Publications

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
www.ncbi.nlm.nih.gov/pubmed/28623233

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
promisneurosciences.com/uncategorized/promis-neurosciences-designates-pmn350-second-lead-product-development-alzheimers-disease/

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

Scopolamine Model

Scopolamine is a competitive antagonist of the M1 muscarinic acetylcholine receptors and widely used to induce cognitive decline in animal models by exerting its anticholinergic and ant muscarinic effects (for review, Klinkenberg&Blokland, 2010). It is used as human medication in e.g. motion sickness. The scopolamine model has recently been described for use in a human cognition models investigating potential cognitive enhancers in healthy volunteers.

SynAging has implemented and validated an in vivo model of scopolamine induced reversible amnesia using mice in a Y-maze assay. Scopolamine impairs several behavioral processes and in particular short-term memory. The model is used extensively for preclinical testing of new compounds with potential to improve cognitive impairment.

Acute i.p. administration of scopolamine induces a fast and reversible decrease of the working memory performances in mice monitored by decreased natural alternation behavior in the Y-maze assay: normal mice alternate between exploring multiple arms in a maze, whereas scopolamine challenged mice show complete lack of orientation.  The SynAging’s team has validated this mouse model, as well as computerized the read-out used, demonstrating that short-term memory deficits induced by scopolamine arereadily reverted by reference drugs such as donepezil (Aricept® used for the symptomatic treatment of Alzheimer’s dementia), rolipram (an inhibitors of phosphodiesterase 4) and RO4491533, a negative allosteric modulator of mGluR2/3.

We are offering this model for the evaluation of your compounds on a competitive fee-for-service basis, providing excellent reproducibility and highly significant results for established reference compounds.